NYSE: WAT · Diagnostics & Research
Waters (WAT) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Waters (WAT) at $337.75 a share. The stock last closed at $453.42, which puts the model's fair value 25.5% below the price. On the model's bands that reads as Overvalued.
Revalued . Price is the close of 16 Nov 2026. Waters Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $337.75, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $453.42 is 25.5% above it: Overvalued, on a high evidence grade.
What's nextNext report on 8 Feb 2027. Options prices imply a move of about 10% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give WAT?
The calibrated range for WAT over 63 trading days is $403.68 to $512.28. It sits around the last close, and its width comes from the volatility that WAT's own options imply (35% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $278.04 to $403.20. In 7% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. It operates through two main divisions: Waters and TA.
Faircurve's model put the fair value at $337.75 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $336.57, so the fair value moved +0.4%. The calibrated range over 63 trading days runs from $403.68 to $512.28. The range is built from the volatility the stock's own options imply, calibrated weekly against realised prices over 8,038 past valuations. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High. It weighs the completeness of the inputs, the number of comparable companies and how closely they agree, and the width of the range of outcomes. It does not say whether the fair value is right.
Waters scores 50 out of 100 on the model's quality measure, a composite of six factors scored against comparable companies. Growth quality is strongest at 98, with trailing revenue growth of 7.0% against a peer median of 3.9%. Profitability scores 0, with ROIC of 1.4% against a peer median of 9.0%. The model compares it with IQVIA Holdings Inc., Agilent Technologies, Inc., IDEXX Laboratories, Inc., Mettler-Toledo International Inc., Illumina, Inc., Quest Diagnostics Incorporated and Medpace Holdings, Inc.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does WAT report earnings, and how has the stock reacted?
Waters's next earnings report is scheduled for 8 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 8.2% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. WAT's 30 day implied volatility works out to about 10.2% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across WAT's last 8 reports, ignoring direction, was 6.6%.
What the options market has priced for a month's move in WAT
How does WAT score on business quality?
Waters's overall quality score is 50 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 0 | 1.4%ROIC | 9.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 75 | 2.97xFCF / net income | 1.10x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 98 | 7.0%Revenue growth, trailing | 3.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 36 | 0.0%Net buybacks / market value | 2.2% |
| Balance sheetNet debt to EBITDA and interest coverage. | 35 | 4.35xNet debt / EBITDA | 1.99x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 82 | 0.9 ptsEBITDA margin downside volatility, 5y | 1.5 pts |
How does WAT compare with similar companies?
The companies in diagnostics & research closest to Waters in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| IQV IQVIA Holdings Inc. | $264.73 | $335.69 | +26.8% | Undervalued |
| A Agilent Technologies, Inc. | $172.92 | $176.09 | +1.8% | Fairly valued |
| IDXX IDEXX Laboratories, Inc. | $700.65 | $568.18 | -18.9% | Overvalued |
| MTD Mettler-Toledo International Inc. | $1,727.26 | $1,679.36 | -2.8% | Fairly valued |
| ILMN Illumina, Inc. | $198.00 | $172.96 | -12.6% | Fairly valued |
| LH Labcorp Holdings Inc. | $372.46 | $465.68 | +25.0% | Low evidence grade |
| DGX Quest Diagnostics Incorporated | $262.21 | $314.32 | +19.9% | Undervalued |
| MEDP Medpace Holdings, Inc. | $648.20 | $717.73 | +10.7% | Fairly valued |
What the comparable companies' multiples alone would give for WAT, the peer-implied price, is $195.44 a share on this run. The fair value weighs that against the company's own multiple.
All diagnostics & research stocks ranked by gap to fair value
Waters at a glance
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA.
- Market value
- $45.2B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $7.1B
- Consensus revenue growth, next fiscal year
- +105.0%
- Analysts with estimates
- 12
- Beta to the US market
- 0.90
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. WAT was not among them.
How the fair value is worked out: the model prices Waters on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for WAT was $336.57. As of 14 Nov 2026 it is $337.75, a change of +0.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Waters's valuation
Is Waters stock undervalued or overvalued?
On Faircurve's model, WAT reads as Overvalued as of 14 Nov 2026. The model's fair value is $337.75 a share against a last close of $453.42, a gap of -25.5%.
What is WAT's fair value?
$337.75 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $278.04 to $403.20.
What price range does the model give WAT?
$403.68 to $512.28 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Waters report earnings next?
The next report is scheduled for 8 Feb 2027. Companies can move their dates.
How much has WAT moved on past earnings reports?
Across its last 8 reports the median two session move was 6.6%, ignoring direction. The largest was +15.8% around the report of 5 May 2026.
How confident is the model in this valuation?
The model's evidence grade for WAT is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on WAT
The model holds no idea open on WAT today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on WAT with their outcomes. A free account is enough.